Trials / Terminated
TerminatedNCT00569179
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CliniMACS CD34 Reagent System | Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2010-04-01
- Completion
- 2010-12-01
- First posted
- 2007-12-07
- Last updated
- 2015-08-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00569179. Inclusion in this directory is not an endorsement.